Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
Antimicrob Agents Chemother
; 61(8)2017 08.
Article
in En
| MEDLINE
| ID: mdl-28584138
ABSTRACT
The 28-day crude mortality rate in 68 cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia started on treatment (within 48 h after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%) than those treated with azole monotherapy (52%) (P = 0.07). After adjusting for confounders, azole monotherapy also was associated with worse 28-day survival (hazard ratio, 3.8; P = 0.003).
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polyenes
/
Azoles
/
Fluconazole
/
Amphotericin B
/
Candida glabrata
/
Echinocandins
/
Candidemia
/
Antifungal Agents
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Antimicrob Agents Chemother
Year:
2017
Type:
Article
Affiliation country:
United States